[1] Long J, Luo GP, Xiao ZW, et al.Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China[J].Cancer Lett, 2014,346(2):273-277.
[2] Müller S, Raulefs S, Bruns P, et al.Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer[J].Mol Cancer, 2015,14(7):94.
[3] ENCODE Project Consortium.An integrated encyclopedia of DNA elements in the human genome[J].Nature, 2012,489(7414):57-74.
[4] Derrien T, Johnson R, Bussotti G, et al.The GENCODEv7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression[J].Genome Res, 2012,22(9):1775-1789.
[5] Wu Z, Liu X, Liu L, et al .Regulation of lncRNA expression[J].Cell Mol Biol Lett, 2014,19(4):561-575.
[6] Wang KC, Chang HY.Molecular mechanisms of long noncoding RNAs[J].Molecular Cell, 2011,43(6):904-914.
[7] ørom UA, Derrien T, Beringer M, et al.Long noncoding RNAs with enhancer- like function in human cells[J].Cell, 2010,143(1):46-58.
[8] Ge X, Chen Y, Liao X, et al.Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer[J].Med On-col, 2013,30(2):588.
[9] Tahira AC, Kubrusly MS, Faria MF, et al.Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer[J].Mol Cancer. 2011,10(11):141.
[10] Li X, Deng SJ, Zhu S, et al.Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway[J].Oncotarget, 2016,7(5):6000-6014.
[11] Gao S, Wang P, Hua Y, et al.ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer[J].Oncotarget. 2016,7(2):1608- 1618.
[12] Jiao F, Hu H, Han T, et al.Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells[J].Int J Mol Sci,2015,16(4):6677-6693.
[13] Fu Z, Chen C, Zhou Q, et al.LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9[J].Cancer Lett,2017,410(23):68-81.
[14] Costache MI, Ioana M, Iordache S, et al.VEGF expression in pancreatic cancer and other malignancies:A review of the literature[J].Rom J Intern Med, 2015,53(3):199-208.
[15] Bergers G, Brekken R, McMahon G, et al.Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis[J].Nat.Cell.Biol.2000,2(10):737-744.
[16] Ma C, Nong K, Zhu H, et al.H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2- mediated EMT[J].Tumor Biol,2014,35(9):9163-9169.
[17] Zheng S, Chen H, Wang Y, et al.Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner[J].Cancer Lett,2016,371(2):354-365.
[18] Hu H, Wang Y, Ding X, et al.Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3[J].Mol Cancer,2018,17(1):18.
[19] Li Z, Zhao X, Zhou Y, et al.The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer[J].J Transl Med,2015,13(3):84.
[20] You L, Chang D, Du HZ, et al.Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells[J]. Biochem.Biophys.Res.Commun.2011,407(1):1-6.
[21] Liu JH, Chen G, Dang YW, et al.Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues[J].Asian Pac J Cancer Prev,2014,15(7):2971-2977.
[22] Ye S, Yang L, Zhao X, et al.Bioinformatics method to predict two regulation mechanism:TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer[J].Cell.Biochem.Biophys.2014,70(3):1849-1858.
[23] Wang Y, Li Z, Zheng S, et al.Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers[J].Oncotarget,2015,6(34):35684-35698.
[24] Hanna N, Ohana P, Konikoff FM, et al.Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer[J].Cancer Gene Ther,2012,19(6):374-381.
[25] Scaiewicz V, Sorin V, Fellig Y, et al.Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer[J].J Oncol,2010,3(12):178-174.
[26] Sorin V, Ohana P, Gallula J, et al.H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer[J].ISRN Oncol,2012,2(6):351-750.
[27] Wang CJ, Shi SB, Tian J, et al.lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients[J].Oncotarget 2017,8(56):95108-95115.
[28] Song J, Xu Q, Zhang H, et al.Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma[J].J Cell Biochem.2018,119(6):4559-4569.
[29] Huang X, Ta N, Zhang Y, et al.Microarray analysis of the expression profile of long non-coding RNAs indicates lncRNA RP11-263F15.1 as a biomarker for diagnosis and prognostic prediction of pancreatic ductal adenocarcinoma[J].J Cancer,2017,8(14):2740-2755.
[30] Chen YC, Liu LC, Ye HY, et al.EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway[J].Am J Cancer Res,2018,8(3):422-434.
[31] Cai H, Yao J, An Y, et al.LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer[J].Oncotarget,2017,8(20):32905-32917.
[32] Cai H, An Y, Chen X, et al.Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of insulin-like growth factor 2[J].Oncotarget,2016,7(52):86857-86870.
[33] Li CH, Xiao Z, Tong JH, et al.EZH2 coupled with HOTAIR to silence microRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma[J].Int J Cancer,2017,140(1):120-129.
[34] Jiang Y, Li Z, Zheng S, et al.The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1[J].Tumor Biol,2016,37(3):3957-3967.
[35] Ma L, Tian X, Wang F, et al.The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma[J].Cancer Biol Ther,2016,17(10):1051-1061.
[36] Zhao L, Kong HR, Sun HW, et al.LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448[J].J.Cell.Physiol.,2018,233(5):4044-4055.
[37] Zhang M, Zhao Y, Zhang Y, et al.LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway[J].Biochim Biophys Acta,2018,1864(5 Pt A):1770-1782.
[38] Zhou Y, Chen Y, Ding W, et al.LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96/FOXO3[J].IUBMB Life,2018,70(4):276-290.
[39] Sun Z, Zhang B, Cui T.Long non-coding RNA XIST exerts oncogenic functions in pancreatic cancer via miR-34a-5p[J].Oncol Rep,2018,39(4):1591-1600.
[40] Wei W, Liu Y, Lu YB, et al.LncRNA XIST promotes pancreatic cancer proliferation through miR-133a/EGFR[J].J Cell Biochem,2017,118(10):3349-3358.
[41] Lian Y, Xiao C, Yan C, et al.Knockdown of pseudogene derived from lncRNA DUXAP10 inhibits cell proliferation, migration, invasion, and promotes apoptosis in pancreatic cancer[J].J Cell Biochem,2018,119(4):3671-3682.
[42] Zhao L, Sun HW, Kong HR, et al.The lncrna-TUG1/EZH2 axis promotes pancreatic cancer cell proliferation, migration and EMT phenotype formation through sponging mir-382[J].Cell.Physiol.Biochem.,2017,42(6):2145-2158.
[43] Li CG, Zhao ZM, Zhou ZP, et al.Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis[J].Cancer Chemoth Pharm,2016,78(6):1199-1207.
[44] Gao ZQ, Wang JF, Chen DH, et al.Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p[J].Biomed.Pharmcother,2018,97:809-817.
